Will Pricing For Gilead’s Sovaldi Set A Ceiling In HCV, Lead To A Price War?

Gilead’s wholesale acquisition cost of $1,000-a-day for Sovaldi met with immediate backlash, as well as foreboding comments from a leading PBM. Observers anticipate a possible pricing war between Gilead and other companies developing new regimens for HCV.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America